Evidence map›Paper›PMID 27928636›Full record

Trial reportClinical and experimental nephrology2017

Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.

Yu-Ming Chang, Shih-Ching Tsai, Chih-Chung Shiao, Hung-Hsiang Liou, Chuan-Lan Yang, Nai-Yu Tung, Kua-Sui Hsu, I-Ling Chen, Mei-Chyn Liu, Jsun-Liang Kao and 2 more

Erratum issuedAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yu-Ming ChangDivision of Nephrology, of Internal Medicine, Department Saint Mary's Hospital Luodong, Yilan, Taiwan.
Shih-Ching TsaiDivision of Nephrology, of Internal Medicine, Department Saint Mary's Hospital Luodong, Yilan, Taiwan.
Chih-Chung ShiaoDivision of Nephrology, of Internal Medicine, Department Saint Mary's Hospital Luodong, Yilan, Taiwan.
Hung-Hsiang LiouDivision of Nephrology, Department of Internal Medicine, Hsin-Jen Hospital, 5th F, 387 Chong-Cheng Road, Xinzhuang District, 242, New Taipei City, Taiwan. hh258527@ms23.hinet.net.
Chuan-Lan YangDepartment of Nursing, Saint Mary's Hospital Luodong, Yilan, Taiwan.
Nai-Yu TungNutrition Room, Saint Mary's Hospital Luodong, Yilan, Taiwan.
Kua-Sui HsuDepartment of Nursing, Saint Mary's Hospital Luodong, Yilan, Taiwan.
I-Ling ChenDepartment of Nursing, Saint Mary's Hospital Luodong, Yilan, Taiwan.
Mei-Chyn LiuDialysis Center, Hsin-Ren Clinics, New Taipei City, Taiwan.
Jsun-Liang KaoDivision of Nephrology, of Internal Medicine, Department Saint Mary's Hospital Luodong, Yilan, Taiwan.
Rong-Na JhenDivision of Nephrology, of Internal Medicine, Department Saint Mary's Hospital Luodong, Yilan, Taiwan.
Ya-Ting HuangDepartment of Nursing, Saint Mary's Hospital Luodong, Yilan, Taiwan.
Saint Mary's Hospital Luodong · TWJen-Ai Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhosphate binders have an impact on fibroblast growth factor 23 (FGF23); however, the effect of phosphate binders on serum hepcidin has not been explored. We conducted a 24-week multicenter randomized controlled trial to investigate the effects of lanthanum carbonate or calcium carbonate monotherapy on serum phosphate, FGF23, and hepcidin levels in chronic hemodialysis patients.

methodsForty-six patients were recruited, and daily dietary phosphorus was controlled between 600-800 mg. Serum calcium, phosphate, albumin, alkaline phosphatase (ALP), FGF23, intact parathyroid hormone (iPTH), hepcidin, high-sensitivity CRP (hsCRP), 25(OH)D, 1,25(OH)

resultsTwenty-five patients completed the study. Mean serum FGF23 level was significantly decreased after a 24-week treatment with lanthanum (8677.5 ± 7490.0 vs. 4692.8 ± 5348.3 pg/mL, p = 0.013, n = 13), but not with calcium (n = 12). The reduction of serum hepcidin in lanthanum group was positively correlated with the decrement of serum phosphate (r = 0.631, p = 0.021) and serum hsCRP (r = 0.670, p = 0.012) levels, respectively. Serum ALP, iPTH, vitamin D, fetuin-A, and osteopontin revealed no significant inter- or intragroup differences.

conclusionsIn summary, a decrease in serum FGF23 levels and a trend of decline in hepcidin levels were observed only in lanthanum group.

Indexed as

Renal DialysisAgedBiomarkersCalcium CarbonateChelating AgentsDown-RegulationFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHepcidinsHumansLanthanumMaleMiddle AgedPhosphatesPhosphorus, DietaryBiomarkersCalcium CarbonateChelating AgentsFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsHAMP protein, humanHepcidinsLanthanumlanthanum carbonatePhosphatesPhosphorus, DietaryFGF23HemodialysisHepcidinPhosphate binders

Identifiers

PMID27928636
OpenAlexW2560264411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.